Income Statement
Quarterly Data

The income statement presents information on the financial results of a company business activities over a period of time. The income statement communicates how much revenue the company generated during a period and what cost it incurred in connection with generating that revenue.

Abbott Laboratories, consolidated income statement (quarterly data)

US$ in millions

3 months ended:	Sep 30, 2025	Jun 30, 2025	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Net sales	11,369)	11,142)	10,358)	10,974)	10,635)	10,377)	9,964)	10,241)	10,143)	9,978)	9,747)	10,091)	10,410)	11,257)	11,895)	11,468)	10,928)	10,223)	10,456)	10,701)	8,853)	7,328)	7,726)
Cost of products sold, excluding amortization of intangible assets	(5,075)	(4,854)	(4,468)	(4,942)	(4,698)	(4,603)	(4,463)	(4,556)	(4,605)	(4,483)	(4,331)	(4,593)	(4,629)	(4,933)	(4,987)	(4,766)	(4,423)	(4,947)	(4,401)	(4,493)	(3,966)	(3,263)	(3,281)
Amortization of intangible assets	(420)	(420)	(420)	(465)	(470)	(471)	(472)	(481)	(496)	(498)	(491)	(496)	(498)	(507)	(512)	(514)	(520)	(504)	(509)	(508)	(510)	(553)	(561)
Gross profit	5,874)	5,868)	5,470)	5,567)	5,467)	5,303)	5,029)	5,204)	5,042)	4,997)	4,925)	5,002)	5,283)	5,817)	6,396)	6,188)	5,985)	4,772)	5,546)	5,700)	4,377)	3,512)	3,884)
Research and development	(766)	(725)	(716)	(749)	(713)	(698)	(684)	(700)	(672)	(715)	(654)	(725)	(782)	(684)	(697)	(762)	(672)	(654)	(654)	(698)	(580)	(564)	(578)
Selling, general and administrative	(3,051)	(3,091)	(3,061)	(2,907)	(2,895)	(2,936)	(2,959)	(2,724)	(2,723)	(2,740)	(2,762)	(2,973)	(2,731)	(2,757)	(2,787)	(3,048)	(2,767)	(2,726)	(2,783)	(2,570)	(2,302)	(2,276)	(2,548)
Operating earnings	2,057)	2,052)	1,693)	1,911)	1,859)	1,669)	1,386)	1,780)	1,647)	1,542)	1,509)	1,304)	1,770)	2,376)	2,912)	2,378)	2,546)	1,392)	2,109)	2,432)	1,495)	672)	758)
Interest expense	(121)	(121)	(131)	(136)	(142)	(140)	(141)	(159)	(166)	(159)	(153)	(154)	(141)	(132)	(131)	(131)	(133)	(134)	(135)	(136)	(137)	(134)	(139)
Interest income	77)	71)	82)	91)	91)	82)	80)	89)	97)	98)	101)	88)	55)	26)	14)	11)	10)	11)	11)	9)	10)	9)	18)
Net foreign exchange gain (loss)	17)	11)	7)	10)	11)	6)	—)	(24)	10)	(21)	(6)	14)	(19)	—)	3)	6)	(4)	—)	(3)	5)	7)	1)	(5)
Other income (expense), net	150)	137)	127)	154)	121)	(10)	111)	109)	83)	176)	111)	68)	93)	82)	78)	63)	74)	79)	61)	78)	46)	(22)	1)
Earnings from continuing operations before taxes	2,180)	2,150)	1,778)	2,030)	1,940)	1,607)	1,436)	1,795)	1,671)	1,636)	1,562)	1,320)	1,758)	2,352)	2,876)	2,327)	2,493)	1,348)	2,043)	2,388)	1,421)	526)	633)
Taxes on earnings from continuing operations	(536)	(371)	(453)	7,199)	(294)	(305)	(211)	(201)	(235)	(261)	(244)	(287)	(323)	(334)	(429)	(338)	(393)	(159)	(250)	(230)	(189)	11)	(89)
Earnings from continuing operations	1,644)	1,779)	1,325)	9,229)	1,646)	1,302)	1,225)	1,594)	1,436)	1,375)	1,318)	1,033)	1,435)	2,018)	2,447)	1,989)	2,100)	1,189)	1,793)	2,158)	1,232)	537)	544)
Net earnings from discontinued operations, net of tax	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	4)	—)	—)	20)
Net earnings	1,644)	1,779)	1,325)	9,229)	1,646)	1,302)	1,225)	1,594)	1,436)	1,375)	1,318)	1,033)	1,435)	2,018)	2,447)	1,989)	2,100)	1,189)	1,793)	2,162)	1,232)	537)	564)

Net Sales: Net sales have shown fluctuations over the periods analyzed, with a notable peak in the fourth quarter of 2020 at 10,701 million USD, followed by a slight decline and stabilization around the 10,000 to 11,000 million USD range in subsequent quarters. There is a trend of moderate growth from early 2023 through the end of 2024, reaching values above 11,000 million USD.
Cost of Products Sold: The cost of products sold excluding amortization has generally increased over time in absolute terms, reflecting an expected rise in direct costs parallel to sales. However, the increase is not always linear, with some quarters showing a reduction or stabilization. Amortization of intangible assets has remained relatively stable, with a very gradual decrease in the latter periods.
Gross Profit: Gross profit demonstrates significant variability, with a peak in the last quarter of 2020 (5,700 million USD) and generally maintaining a level between 4,900 and 5,900 million USD in the following years. Despite fluctuations in sales and costs, gross profit margins appear to have had some pressure but generally sustain positive momentum, especially in most recent quarters.
Research and Development Expenses: R&D expenses exhibit variability but tend to hover between 650 and 760 million USD quarterly. There is recurrent seasonal variation, but no clear long-term upward or downward trend is discernible. These investments reflect sustained commitment to product and technology development.
Selling, General, and Administrative Expenses: SG&A expenses consistently range between approximately 2,500 and 3,100 million USD per quarter, with some noticeable peaks in certain quarters, particularly in the latter part of the period analyzed where expenses seem to increase slightly. This indicates a steady expense base with potential incremental costs associated with sales and administrative functions.
Operating Earnings: Operating earnings show pronounced quarter-to-quarter variation, with a significant peak in Q4 2020 (2,432 million USD) followed by fluctuating decreases and recoveries. The range broadly lies between 1,300 and 2,000 million USD, indicating operational performance impacted by variable factors but maintaining profitability.
Interest Income and Expense: Interest expense remains relatively consistent around 130 to 160 million USD per quarter, showing a modest declining trend in later quarters. Interest income exhibits an increasing trend, jumping from single-digit values to between 70 and 100 million USD quarterly by 2022-2023, suggesting better cash management or higher returns on investments.
Foreign Exchange and Other Income/Expense: Foreign exchange gains and losses demonstrate high volatility, alternating between gains and losses without a persistent trend. Other income (expense), net, shows an overall positive trajectory with increasing income in recent periods, suggesting favorable non-operating financial activities or settlements.
Earnings Before Taxes: Earnings before taxes closely follow operating earnings trends, with highs reflecting the peaks in operational profitability. There is notable volatility but no consistent long-term upward or downward movement is evident, highlighting susceptibility to external factors.
Taxes on Earnings: Tax figures fluctuate substantially, with occasional negative tax values and a significant spike in Q1 2025, which may indicate adjustments, deferred tax items, or extraordinary tax events. This irregularity affects effective tax rates from quarter to quarter, making tax expense analysis complex.
Earnings from Continuing Operations: Continuing operations earnings trend positively with cyclical variability. The spike in early 2025 is notable and distorts the trend temporarily. Overall, earnings remain solid, supporting business continuity and indicating resilient profitability despite external and internal operational variations.
Net Earnings: Net earnings overall mirror continuing operations with the addition of minor contributions from discontinued operations in some quarters. The stability and growth in net earnings demonstrate the company's capacity to generate profit consistently, notwithstanding interim fluctuations due to tax or other non-recurring items.

Download chart

Abbott Laboratories (NYSE:ABT)

Income Statement Quarterly Data

Income Statement
Quarterly Data